115 related articles for article (PubMed ID: 21077465)
1. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications.
Dovern E; de Hingh IH; Verwaal VJ; van Driel WJ; Nienhuijs SW
Eur J Gynaecol Oncol; 2010; 31(3):256-61. PubMed ID: 21077465
[TBL] [Abstract][Full Text] [Related]
2. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.
Chua TC; Robertson G; Liauw W; Farrell R; Yan TD; Morris DL
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1637-45. PubMed ID: 19701772
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
[TBL] [Abstract][Full Text] [Related]
6. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
8. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
9. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.
Hotouras A; Desai D; Bhan C; Murphy J; Lampe B; Sugarbaker PH
Int J Gynecol Cancer; 2016 May; 26(4):661-70. PubMed ID: 26844612
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer - A single tertiary institution experience.
Kocic M; Nikolic S; Zegarac M; Djurisic I; Soldatovic I; Milenkovic P; Kocic J
J BUON; 2016; 21(5):1176-1183. PubMed ID: 27837620
[TBL] [Abstract][Full Text] [Related]
15. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
16. Combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as a treatment for recurrent epithelial ovarian cancer-National Cancer Institute experience.
Fahim MI; Nassar OA; Mansour OM; Ali AM; Mahmoud AM; Allam RM; Kamal A
J Egypt Natl Canc Inst; 2018 Dec; 30(4):139-141. PubMed ID: 30470604
[TBL] [Abstract][Full Text] [Related]
17. Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy.
Arjona-Sanchez A; Rufian-Peña S; Artiles M; Sánchez-Hidalgo JM; Casado-Adam Á; Cosano A; Thoelecke H; Ramnarine S; Garcilazo D; Briceño-Delgado J
Int J Hyperthermia; 2018 Aug; 34(5):570-577. PubMed ID: 29298538
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
Mulier S; Claes JP; Dierieck V; Amiel JO; Pahaut JP; Marcelis L; Bastin F; Vanderbeeken D; Finet C; Cran S; Velu T
Curr Pharm Des; 2012; 18(25):3793-803. PubMed ID: 22591422
[TBL] [Abstract][Full Text] [Related]
19. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
20. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
Cascales Campos P; Gil J; Parrilla P
Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]